James R. Birkenstamm

FDA investigator

Appears on 12 documents from 2018 to 2026, mostly at sites in New Jersey. Most often cites responsibilities of quality control unit (21 CFR 211.22).

12
Documents on file
5.1
Observations per 483
2018
First seen
2026
Most recent

What they cite most

From 61 observations

Activity by year

2018: 2, 2019: 1, 2023: 3, 2024: 3, 2025: 2, 2026: 1

Where

New Jersey 9 · Maryland 1 · Taiwan 1 · Thailand 1

Is James R. Birkenstamm coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

12 documents, newest first
FirmOpen
483 Safrel Pharmaceuticals LLCJan 30, 2026 · Dayton, New Jersey
483 Acino Products, LLCMay 21, 2025 · Hamilton, New Jersey
483 Tulex Pharmaceuticals IncMar 24, 2025 · Cranbury, New Jersey
483 Health and Natural Beauty USA CorpOct 15, 2024 · Piscataway, New Jersey
483 AstraZeneca Pharmaceuticals LPMay 31, 2024 · Gaithersburg, Maryland
483 Nang Kuang Pharmaceutical Co. Ltd.Apr 2, 2024 · Tainan City, Taiwan
483 S & J INTERNATIONAL ENTERPRISES PUBLIC COMPANY LIMITED BRANCHJul 21, 2023 · SI RACHA, Thailand

About this profile

What does James R. Birkenstamm inspect?

James R. Birkenstamm appears on 12 documents on file covering 12 sites, mostly in New Jersey.

What do they cite most often?

21 CFR 211.22 (responsibilities of quality control unit), followed by 21 CFR 211.42 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for James R. Birkenstamm is dated Jan 30, 2026.